XML 38 R26.htm IDEA: XBRL DOCUMENT
v3.25.3

Collaborations, contracts and licensing agreements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Revenue from Contract with Customer [Abstract] |
Summary of collaborations | Revenues are summarized in the following table:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
| (in thousands) |  | (in thousands)
Revenue from collaborations and licenses
Acuitas Therapeutics, Inc. | $ | 280 |  |  | $ | 644 |  |  | $ | 1,375 |  |  | $ | 1,981 |
Qilu Pharmaceutical Co., Ltd. | — |  |  | 123 |  |  | 10,434 |  |  | 880 |
Non-cash royalty revenue |  |  |  |  |  |  |
Alnylam Pharmaceuticals, Inc. | 249 |  |  | 572 |  |  | 1,223 |  |  | 1,736 |
Total revenue | $ | 529 |  |  | $ | 1,339 |  |  | $ | 13,032 |  |  | $ | 4,597 |

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration